Co-Diagnostics, Inc. (CODX): Entry into a Material Definitive Agreement
Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Loan Transaction with J.J. Astor & Co. On October 9, 2026, Co-Diagnostics, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with J.J. Astor & Co. (the “Lender”), pursuant to
How this was made
The 30-second read
Why it matters
The financing provides immediate liquidity but introduces conversion risk and high default interest, likely pressuring the share price in the short term.
Market read
First‑report disclosure of a material financing agreement for a micro‑cap biotech, modest trading relevance.
What to watch
The loan's conversion price floor and make‑whole provisions may limit dilution if the stock trades above the floor, mitigating downside.
Background
The filing details the terms of a senior secured convertible loan, including fees, conversion mechanics, and ATM waterfall distribution.
Ticker impact
Co-Diagnostics filed an 8‑K reporting a senior secured convertible loan of up to $3.1 million, including an initial $2.1 million draw and convertible notes.
potential downside as conversion dilution and debt service pressure the share price
New convertible loan creates future share issuance risk and a 19% default interest rate, which markets typically view as bearish for small‑cap equities.
Market effects
May signal increased financing activity in the diagnostics sector, but the small size limits broader impact.
Limited to US micro‑cap investors; no significant regional effect.
Low; the deal is company‑specific and does not affect global markets.
Counterpoint
The cash infusion could fund growth initiatives that outweigh dilution concerns, offering upside potential.
Key entities
- companyCo-Diagnostics, Inc.
Issuer of the convertible loan.
- lenderJ.J. Astor & Co.
Provider of the senior secured convertible loan.
